Compare · NTRB vs STE
NTRB vs STE
Side-by-side comparison of Nutriband Inc. (NTRB) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRB and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $25.00B, about 367.9x NTRB ($68.0M).
- STE has been more active in the news (13 items in the past 4 weeks vs 1 for NTRB).
- STE has more recent analyst coverage (18 ratings vs 1 for NTRB).
- Company
- Nutriband Inc.
- STERIS plc (Ireland)
- Price
- -
- -
- Market cap
- $68.0M
- $25.00B
- 1M return
- -
- +16.02%
- 1Y return
- -
- -0.04%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 13
- Recent ratings
- 1
- 18
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest NTRB
- Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
- Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
- Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
- SEC Form 25-NSE filed by Nutriband Inc.
- Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
- Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Latest STE
- Sr. VP and GM, Life Sciences Julia Madsen sold $531,960 worth of Ordinary Shares (2,046 units at $260.00), decreasing direct ownership by 17% to 10,211 units (SEC Form 4)
- Steris upgraded by Jefferies with a new price target
- Director Sohi Mohsen exercised 4,893 units of Ordinary Shares at a strike of $114.74 and sold $1,239,008 worth of Ordinary Shares (4,893 units at $253.22) (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L exercised 5,880 units of Ordinary Shares at a strike of $147.05 and sold $1,503,046 worth of Ordinary Shares (5,880 units at $255.62) (SEC Form 4)
- STERIS plc (Ireland) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 10-Q filed by STERIS plc (Ireland)
- STERIS plc (Ireland) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits